Tag: Reduces
Study Shows Intensive Blood Pressure Control Reduces Risk Of Mild Cognitive Impairment (MCI) And The Combined Risk Of MCI And Dementia

Study Shows Intensive Blood Pressure Control Reduces Risk Of Mild Cognitive Impairment (MCI) And The Combined Risk Of MCI And Dementia

Plus: - Genomic Analysis of Alzheimer's Study May Enable a Precision Medicine Approach CHICAGO, July 25, 2018 /PRNewswire/ -- Significant reductions in the risk of mild ...

Lees verder
AAIC® 2018 Features First Clinical Trial to Show Intensive Blood Pressure Treatment Reduces New Cases of Mild Cognitive Impairment and Dementia (

AAIC® 2018 Features First Clinical Trial to Show Intensive Blood Pressure Treatment Reduces New Cases of Mild Cognitive Impairment and Dementia (

CONFERENCE ALSO RELEASES FIRST-EVER DEMENTIA DATA IN LGB SENIORS, AND WOMEN'S DEMENTIA RISK RELATED TO REPRODUCTIVE HISTORY CHICAGO, July 25, 2018 /PRNewswire/ -- The first ...

Lees verder
Ryzodeg® Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan

Ryzodeg® Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan

ABU DHABI, UAE, December 7, 2017 /PRNewswire/ -- In people with type 2 diabetes who fast during Ramadan, Ryzodeg(R) (insulin degludec/insulin aspart) reduced the overall rate ...

Lees verder
Tresiba® Reduces Hypoglycaemia Regardless of Blood Sugar Level

Tresiba® Reduces Hypoglycaemia Regardless of Blood Sugar Level

ABU DHABI, UAE, December 7, 2017 /PRNewswire/ -- People with either type 1 or type 2 diabetes treated with Tresiba(R) had fewer episodes of low blood sugar (hypoglycaemia) ...

Lees verder
Xultophy® Reduces Cardiovascular Risk Factors in People with Type 2 Diabetes

Xultophy® Reduces Cardiovascular Risk Factors in People with Type 2 Diabetes

LISBON, Portugal, September 13, 2017 /PRNewswire/ -- Oral Presentation 113  In people with type 2 diabetes, Xultophy(R) (insulin degludec/liraglutide) significantly reduced a ...

Lees verder
Victoza® Reduces the Risk of Major Cardiovascular Events in People with Type 2 Diabetes With or Without Prior Events

Victoza® Reduces the Risk of Major Cardiovascular Events in People with Type 2 Diabetes With or Without Prior Events

BARCELONA, Spain, August 28, 2017 /PRNewswire/ -- Oral Presentation 3909 A new analysis of the landmark LEADER trial shows that Victoza(R) (liraglutide) reduced the risk of ...

Lees verder
BizPress.nl